Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study evaluate the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase
inhibitors, also known as "statins" in the treatment of growth and skeletal abnormalities in
children with Noonan syndrome. Half of patients will receive simvastatin while the other half
will receive a placebo.